Andrew Hollman Meyer
Chief Business Officer at Janux Therapeutics, Inc. (JANX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $737K
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jan 2SEC | JANXJanux Therapeutics, Inc. | Sell | 1,87983,095 held (−2%) | $13.73 | $26K | +33.9% |
| Dec 3SEC | JANXJanux Therapeutics, Inc. | Sell Plan | 2,70085,607 held (−3%) | $32.85 | $89K | -44.0% |
| Dec 3SEC | JANXJanux Therapeutics, Inc. | Sell Plan | 63384,974 held (−1%) | $33.52 | $21K | -45.1% |
| Nov 14SEC | JANXJanux Therapeutics, Inc. | Sell Plan | 3,33384,974 held (−4%) | $30.00 | $100K | -38.7% |
| Oct 30SEC | JANXJanux Therapeutics, Inc. | Sell Plan | 16,66582,139 held (−17%) | $30.06 | $501K | -38.8% |
- Sell
Chief Business Officer Andrew Hollman Meyer sold $89K of JANX at $32.85 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Business Officer Andrew Hollman Meyer sold $21K of JANX at $33.52 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Business Officer Andrew Hollman Meyer sold $100K of JANX at $30.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Business Officer Andrew Hollman Meyer sold $501K of JANX at $30.06 — pre-scheduled 10b5-1 plan sale.